Investigating Tralokinumab-Related Adverse Events in Treating Atopic Dermatitis: Insights from the FAERS Database

    February 2026 in “ Frontiers in Immunology ”
    Yueping Jiang, Xinjuan Sun, Yang Li
    Studysummary In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on public-pages-files-2025.frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Tralokinumab as a Therapeutic Option for Patients with Concurrent Atopic Dermatitis and Alopecia Areata International Journal of Dermatology · 2024
    2. Drug-Induced Alopecia After Dupilumab Therapy JAAD case reports · 2018
    3. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    4. A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata Expert Opinion on Biological Therapy · 2016
    5. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015